ADMA Biologics, Inc. (ADMA) stock
Close on Nov 11, 2026Market cap $2.95BP/E 17.1Yield –
ADMA Biologics, Inc. grew revenue 6.3% to $519.15M over the twelve months to Sep 30, 2026. Operating income rose 44.4% to $241.23M, moving the operating margin from 34.2% to 46.5%. Free cash flow was $132.91M, up 226.4% from a year earlier. At the latest close the market valued the company at $2.95B, 17.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.95B
- P/E ratio
- 17.1
- Price to sales
- 5.69
- Price to book
- 6.74
- Dividend yield
- –
- Free cash flow yield
- 4.50%
Fundamentals
- Revenue
- $519.15M
- Net income
- $182.41M
- EPS, diluted
- $0.77
- Free cash flow
- $132.91M
- Book value per share
- $1.94
- Diluted shares
- 226M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $12.67
- Open
- $12.71
- Day's range
- $12.60 – $13.28
- Volume
- 2,564,586
- Average volume (20 days)
- 4,062,894
- Index membership
- S&P SmallCap 600 (since Nov 2024), Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- Beta (5 years)
- 0.63
- 52-week range
- $7.21 – $20.46
- RSI (14 days)
- 68.0
- Volatility (1 year)
- 59.6%
- Relative volume
- 0.86×
- WACC
- 7.8%
On 4 of our idea lists: Undervalued and financially sound, Buyback cannibals, Shareholder yield, Stocking up
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADMA | S&P 500 | Difference | ADMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +27.3% | -2.4% | +29.7 pts | ||
| 3 months | +33.2% | -1.2% | +34.3 pts | ||
| Year to date | -27.7% | +12.3% | −40.0 pts | ||
| 1 year | -17.7% | +12.4% | −30.2 pts | ||
| 3 years | +249.9% | +78.8% | +171.1 pts | +51.8% | +21.4% |
| 5 years | +729.6% | +75.2% | +654.4 pts | +52.7% | +11.9% |
| 10 years | +106.7% | +311.1% | −204.4 pts | +7.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ADMA Biologics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV TM to Include Pediatric ImmuneNews
- Update
- Update
About ADMA Biologics
Biological Products, (No Diagnostic Substances)
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. It operates through two segments: ADMA BioManufacturing and Plasma Collection Centers. Its commercial therapies include ASCENIV and BIVIGAM, which treat primary humoral immunodeficiency, and Nabi-HB for hepatitis B exposure. The company also offers contract manufacturing and laboratory services. Its products serve physician specialists, hospitals, home infusion providers, and clinics treating immune-compromised patients, while collected plasma is also distributed to third-party manufacturers.
Company profile, executives and historyADMA Biologics stock: common questions
What is ADMA Biologics's stock price?
ADMA closed at $13.19 on Nov 11, 2026, up 4.10% on the day. Over the past 52 weeks it traded between $7.21 and $20.46.
What is ADMA Biologics's market cap?
ADMA Biologics was worth $2.95B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ADMA's P/E ratio?
ADMA trades at 17.1 times earnings, based on diluted earnings per share of $0.77 over the twelve months to Sep 30, 2026.
How much revenue does ADMA Biologics make?
ADMA Biologics reported revenue of $519.15M for the twelve months to Sep 30, 2026, up 6.3% from a year earlier.
Does ADMA Biologics pay a dividend?
No. ADMA Biologics has not paid a cash dividend over the last twelve months.
When does ADMA Biologics report earnings next?
ADMA Biologics is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ADMA stock performed over the past year?
Including dividends, ADMA returned -17.7% over the past year, against +12.4% for the S&P 500.
How many ADMA shares are sold short?
18M shares were sold short at the latest FINRA report, 8.30% of the float, or 7.1 days of average trading volume.
Who are ADMA Biologics's competitors?
Companies most similar to ADMA Biologics by business, industry and size include RGEN, ALVO, KMDA, KRYS, IOVA.
See a number that looks wrong?